CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma	66
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	42
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel	42
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies	34
Issue Information	33
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action	30
gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve	30
Development and application of a pediatric mechanistic kidney model	30
Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids	30
Issue Information	30
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients	27
Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	27
Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform	26
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	24
Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients	23
	23
	23
Issue Information	21
LaTeX tutorial for the standardization and automation of population analysis reports	21
Issue Information	19
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	19
Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling	19
Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome	18
	18
Perspectives on training quantitative systems pharmacologists	18

The Asian Pharmacometrics Network: The historical background, establishment, objectives and roles, and recent activities	18
Issue Information	17
A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer	17
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	17
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	17
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	17
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab	17
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development	16
Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania	16
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	16
	16
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis	15
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy	15
Altered intravenous drug disposition in people living with cystic fibrosis: A meta‐analysis integrating top‐down and bottom‐up data	15
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	15
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	15
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris	14
PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria	14
Issue Information	14
Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis	14
Issue Information	14
A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials	14
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	13
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	13
Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab	13
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models	13
	13
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	13
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology	12
End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor	12
Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox	12
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients	12
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics	12
	12
SAMBA: A novel method for fast automatic model building in nonlinear mixed‐effects models	12
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	11
PBPK‐Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population	11
Exploration of the potential impact of batch‐to‐batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products	11
Enhanced Sensitivity to Tramadol in Diabetic Neuropathic Pain Compared to Nerve Compression Neuropathies: A Population PK/PD Model Analysis	11
	11
Comparing Scientific Machine Learning With Population Pharmacokinetic and Classical Machine Learning Approaches for Prediction of Drug Concentrations	11
Pharmacometric and statistical considerations for dose optimization	11
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	11
	11
Issue Information	11
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	11
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	10
Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder	10
Issue Information	10
Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy	10

Tumor growth inhibition modeling to support the starting dose for dacomitinib	10
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor	10
Efficient and relevant stepwise covariate model building for pharmacometrics	10
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	10
Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions	10
Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment	10
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy	10
Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models	10
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	10
Evaluation of covariate effects in item response theory models	10
Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibo	10
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	10
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	9
A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease	9
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	9
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid	9
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients	9
Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19	9
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	9
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	9
Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions	9
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	8
Correction to: Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first‐line gastric cancer and elevated plasma VEGF‐A	8
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr	8
WITHDRAWAL: Quantitative modeling of approved and emerging therapeutics for modifying TTR levels in patients with Transthyretin Amyloid Cardiomyopathy	8
Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma	8
Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model	8
Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass	8
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	8
Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib	8
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	8
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	8
Hallmarks of neurodegenerative disease: A systems pharmacology perspective	8
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	8
Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making	8
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report	8
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	8
Correction to “Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution”	8
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study	8
Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children	8
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	8
Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling	8
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs	7
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	7
Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment	7
Response to ‘Modeling is data driven: Use it for successful virtual patient generation’	7
Evaluation framework for systems models	7
Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network	7
A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody	7
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women	7
Network module‐based drug repositioning for pulmonary arterial hypertension	7
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	7
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
Cluster Gauss‐Newton method for a quick approximation of profile likelihood: With application to physiologically‐based pharmacokinetic models	7
Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling	7
Issue Information	7
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization	7
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes	7
Exposure‐response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimus	7
A multistate platform model for time‐to‐event endpoints in oncology clinical trials	7
	7
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	6
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	6
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	6
Mechanistic modeling of drug products applied to the skin: A workshop summary report	6
Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes	6
A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation	6
US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer	6
Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine	6
	6
Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias	6
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression	6
Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria	6
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic	6
Cell‐level systems biology model to study inflammatory bowel diseases and their treatment options	6
Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals	6
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients	6
Nonparametric goodness‐of‐fit testing for parametric covariate models in pharmacometric analyses	6
Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers	6

Issue Information	6
Issue Information	6
	6
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility	6
Moving the needle for oncology dose optimization: A call for action	6
Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia	6
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study	6
Response to “mixed‐effects models and the drug titration paradox”	6
Issue Information	6
Issue Information	6
Can a propensity score matching method be applied to assessing efficacy from single‐arm proof‐of‐concept trials in oncology?	6
Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations	6
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors	6
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	6
Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid ca	6
Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework	6
A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria	6
Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma	5
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	5
Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab	5
Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients	5
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	5
Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions	5
Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates	5
Issue Information	5
Perspective on model‐informed drug development	5
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions	5
Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer	5
Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator	5
Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies	5
Comprehensive Parent‐Metabolite PBPK/PD Modeling Insights Into Methotrexate Personalized Dosing Strategies in Patients With Rheumatoid Arthritis	5
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	5
Delineating gene–environment effects using virtual twins of patients treated with clozapine	5
N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner—A pharmacokinetic/pharmacodynamic analysis	5
Is PBPK useful to inform product label on managing clinically significant drug interactions mediated by cytokine release syndrome?	5
Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers	5
	5
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide	5
Issue Information	5
Issue Information	5